New research suggests that individuals who discontinue new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass at a significantly accelerated pace than those who end traditional lifestyle plans.
Published data in a major health publication demonstrates that while obese individuals can lose a large proportion of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Users using these medications need to be informed of the potential of quick weight regain when the medication concludes," warns expert Dr. Susan Jebb.
Such speed of regain means a reversion to pre-treatment mass within about one and a half years.
Weighing Treatments
The analysis, which looked at dozens of trials involving over 9,000 of patients, contrasted the outcomes of the injectable medications with other pills.
Researchers point out that individuals who lose weight through lifestyle changes alone generally see a slower weight regain—around 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Doctors believe the way of the drugs explains the accelerated regain.
These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Long-term administration of GLP-1 concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in hunger is uncontrolled, making overeating far more likely."
A Chronic Disease?
Medical guidelines advise the jabs for individuals with obesity-related medical conditions, accompanied by prescribed lifestyle changes.
Many experts argue that, given the significant potential of weight regain, the treatment is often ongoing.
This opinion is echoed by drug manufacturers, who state that the findings "emphasize the persistent character of obesity," comparing it to managing diseases like hypertension.
User Experiences
Users who have stopped the medication describe a powerful resurgence of appetite.
"It was like something that goes on and I was suddenly ravenous," said one woman.
This challenge is compounded if patients have not established sustainable lifestyle or habit modifications during treatment.
Widespread Use
Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is more common among females compared to men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while these medications are potent tools for shedding pounds, they are not a standalone fix and lasting health benefits relies on combined behavioural support.
